Table of Content

1. Executive Summary
1.1. Global Erectile Dysfunction Drugs Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Drug Lifecycle Analysis
2.4. Global Erectile Dysfunction Drugs Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape
3. Global Erectile Dysfunction Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2013-2016
3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Erectile Dysfunction Drugs Market Outlook: Drug
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug, 2018 - 2022
3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
3.3.3.1. Viagra
3.3.3.2. Cialis
3.3.3.3. Staxyn/Levitra
3.3.3.4. Stendra/Spedra
3.3.3.5. Others
3.4. Market Attractiveness Analysis: Drug
3.5. Global Erectile Dysfunction Drugs Market Outlook: Distribution Channel
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2018 - 2022
3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
3.5.3.1. Hospital Pharmacies
3.5.3.2. Retail Pharmacies
3.5.3.3. Online Pharmacies
3.6. Market Attractiveness Analysis: Distribution Channel
4. Global Erectile Dysfunction Drugs Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia and Oceania
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Global Erectile Dysfunction Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
5.3.1. By Country
5.3.2. By Drug
5.3.3. By Distribution Channel
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
5.5.1. Viagra
5.5.2. Cialis
5.5.3. Staxyn/Levitra
5.5.4. Stendra/Spedra
5.5.5. Others
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
5.6.1. Hospital Pharmacies
5.6.2. Retail Pharmacies
5.6.3. Online Pharmacies
5.7. Market Attractiveness Analysis
6. Europe Global Erectile Dysfunction Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Drug
6.3.3. By Distribution Channel
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Türkiye
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
6.5.1. Viagra
6.5.2. Cialis
6.5.3. Staxyn/Levitra
6.5.4. Stendra/Spedra
6.5.5. Others
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
6.6.1. Hospital Pharmacies
6.6.2. Retail Pharmacies
6.6.3. Online Pharmacies
6.7. Market Attractiveness Analysis
7. East Asia Global Erectile Dysfunction Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Drug
7.3.3. By Distribution Channel
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
7.5.1. Viagra
7.5.2. Cialis
7.5.3. Staxyn/Levitra
7.5.4. Stendra/Spedra
7.5.5. Others
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
7.6.1. Hospital Pharmacies
7.6.2. Retail Pharmacies
7.6.3. Online Pharmacies
7.7. Market Attractiveness Analysis
8. South Asia & Oceania Global Erectile Dysfunction Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Drug
8.3.3. By Distribution Channel
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
8.5.1. Viagra
8.5.2. Cialis
8.5.3. Staxyn/Levitra
8.5.4. Stendra/Spedra
8.5.5. Others
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
8.6.1. Hospital Pharmacies
8.6.2. Retail Pharmacies
8.6.3. Online Pharmacies
8.7. Market Attractiveness Analysis
9. Latin America Global Erectile Dysfunction Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Drug
9.3.3. By Distribution Channel
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
9.5.1. Viagra
9.5.2. Cialis
9.5.3. Staxyn/Levitra
9.5.4. Stendra/Spedra
9.5.5. Others
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
9.6.1. Hospital Pharmacies
9.6.2. Retail Pharmacies
9.6.3. Online Pharmacies
9.7. Market Attractiveness Analysis
10. Middle East & Africa Global Erectile Dysfunction Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Drug
10.3.3. By Distribution Channel
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug, 2023 - 2030
10.5.1. Viagra
10.5.2. Cialis
10.5.3. Staxyn/Levitra
10.5.4. Stendra/Spedra
10.5.5. Others
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
10.6.1. Hospital Pharmacies
10.6.2. Retail Pharmacies
10.6.3. Online Pharmacies
10.7. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2022
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Analog IC
11.2.3. Apparent Drug Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Pfizer, Inc.
11.3.1.1. Overview
11.3.1.2. Segments and Drug
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. Dong-A ST Co., Ltd.
11.3.2.1. Overview
11.3.2.2. Segments and Drug
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Eli Lilly and Company
11.3.3.1. Overview
11.3.3.2. Segments and Drug
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. Bayer AG
11.3.4.1. Overview
11.3.4.2. Segments and Drug
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Vivus, Inc.
11.3.5.1. Overview
11.3.5.2. Segments and Drug
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Teva Pharmaceutical Industries Ltd.
11.3.6.1. Overview
11.3.6.2. Segments and Drug
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. SK Chemicals
11.3.7.1. Overview
11.3.7.2. Segments and Drug
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. Meda Pharmaceuticals, Inc.
11.3.8.1. Overview
11.3.8.2. Segments and Drug
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Futura Medical plc
11.3.9.1. Overview
11.3.9.2. Segments and Drug
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations